Carlos J. Toro-Huamanchumo

Dr. Carlos J. Toro-Huamanchumo

Universidad San Ignacio de Loyola, Lima, Peru
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2024 in eClinicalMedicine
Verified
Journal Article
Open access
XZXiao-Dong Zhou
Xiao-Dong Zhou
QCQin-Fen Chen
Qin-Fen Chen
WYWah Yang
Wah Yang
MZMauricio Zuluaga
Mauricio Zuluaga
GTGiovanni Targher
Giovanni Targher
MZMing-Hua Zheng
Ming-Hua Zheng
Obesity represents a major global health challenge with important clinical implications. Despite its recognized importance, the global disease burden attributable to high body mass index (BMI) remains less well understood. We systematically analyzed global deaths and disability-adjusted life years (DALYs) attributable to high BMI using the methodology and analytical approaches of the Global Burden of Disease Study (GBD) 2021. High BMI was defined as a BMI over 25 kg/m2 for individuals aged ≥20 years. The Socio-Demographic Index (SDI) was used as a composite measure to assess the level of socio-economic development across different regions. Subgroup analyses considered age, sex, year, geographical location, and SDI. From 1990 to 2021, the global deaths and DALYs attributable to high BMI increased more than 2.5-fold for females and males. However, the age-standardized death rates remained stable for females and increased by 15.0% for males. Similarly, the age-standardized DALY rates increased by 21.7% for females and 31.2% for males. In 2021, the six leading causes of high BMI-attributable DALYs were diabetes mellitus, ischemic heart disease, hypertensive heart disease, chronic kidney disease, low back pain and stroke. From 1990 to 2021, low-middle SDI countries exhibited the highest annual percentage changes in age-standardized DALY rates, whereas high SDI countries showed the lowest. The worldwide health burden attributable to high BMI has grown significantly between 1990 and 2021. The increasing global rates of high BMI and the associated disease burden highlight the urgent need for regular surveillance and monitoring of BMI. 10.13039/501100001809 National Natural Science Foundation of China and National Key R&D Program of China.

1 January 2019 in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Verified
Journal Article
Closed access
BPBetzi Pantoja-Torres
Betzi Pantoja-Torres
CTCarlos J. Toro-Huamanchumo
Carlos J. Toro-Huamanchumo
DUDiego Urrunaga-Pastor
Diego Urrunaga-Pastor
MGMirella Guarnizo-Poma
Mirella Guarnizo-Poma
HLHerbert Lazaro-Alcantara
Herbert Lazaro-Alcantara
VBVicente Aleixandre Benites-Zapata
Vicente Aleixandre Benites-Zapata

1 January 2019 in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Verified
Journal Article
Closed access
CTCarlos J. Toro-Huamanchumo
Carlos J. Toro-Huamanchumo
DUDiego Urrunaga-Pastor
Diego Urrunaga-Pastor
MGMirella Guarnizo-Poma
Mirella Guarnizo-Poma
HLHerbert Lazaro-Alcantara
Herbert Lazaro-Alcantara
SPSocorro Paico-Palacios
Socorro Paico-Palacios
VBVicente Aleixandre Benites-Zapata
Vicente Aleixandre Benites-Zapata

26 July 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HDHilda V. Durango-Chavez
Hilda V. Durango-Chavez
CTCarlos J. Toro-Huamanchumo
Carlos J. Toro-Huamanchumo
WSWilmer Silva-Caso
Wilmer Silva-Caso
JLJohanna Martins Luna
Johanna Martins Luna
MAMiguel Angel Aguilar-Luis
Miguel Angel Aguilar-Luis
ZPZully M. Puyen
Zully M. Puyen
Background: Oropouche fever is an infectious disease caused by the Oropouche virus (OROV). The diagnosis and prediction of the clinical picture continue to be a great challenge for clinicians who manage patients with acute febrile syndrome. Several symptoms have been associated with OROV virus infection in patients with febrile syndrome; however, to date, there is no clinical prediction rule, which is a fundamental tool to help the approach of this infectious disease.Objective: To assess the performance of a prediction model based solely on signs and symptoms to diagnose Oropouche virus infection in patients with acute febrile syndrome.Materials and methods: Validation study, which included 923 patients with acute febrile syndrome registered in the Epidemiological Surveillance database of three arbovirus endemic areas in Peru.Results: A total of 97 patients (19%) were positive for OROV infection in the development group and 23.6% in the validation group. The area under the curve was 0.65 and the sensitivity, specificity, PPV, NPV, LR + and LR- were 78.2%, 35.1%, 27.6%, 83.6%, 1.20 and 0.62, respectively.Conclusions: The development of a clinical prediction model for the diagnosis of Oropouche based solely on signs and symptoms does not work well. This may be due to the fact that the symptoms are nonspecific and related to other arbovirus infections, which confuse and make it difficult to predict the diagnosis, especially in endemic areas of co-infection of these diseases. For this reason, epidemiological surveillance of OROV in various settings using laboratory tests such as PCR is important.

14 November 2024 in Clinical Nutrition
Verified
Journal Article
Closed access
XZXiao-Dong Zhou
Xiao-Dong Zhou
QCQin-Fen Chen
Qin-Fen Chen
Giovanni TargherGiovanni Targher
Giovanni Targher
CBChris Byrne
Chris Byrne
CMChristos S. Mantzoros
Christos S. Mantzoros
MZMing-Hua Zheng
Ming-Hua Zheng

1 January 2019 in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Verified
Journal Article
Closed access
VBVicente Aleixandre Benites-Zapata
Vicente Aleixandre Benites-Zapata
CTCarlos J. Toro-Huamanchumo
Carlos J. Toro-Huamanchumo
DUDiego Urrunaga-Pastor
Diego Urrunaga-Pastor
MGMirella Guarnizo-Poma
Mirella Guarnizo-Poma
HLHerbert Lazaro-Alcantara
Herbert Lazaro-Alcantara
VRVitalia del Carmen Ranilla-Seguin
Vitalia del Carmen Ranilla-Seguin